$1.64B in CY2024 Part D spend2.1M claims · 486K beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Linagliptin used for?
JENTADUETO XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus .
Is there a generic for Linagliptin?
Yes. 7 ANDAs filed at FDA, 7 generic manufacturers currently shipping.
How much does my plan pay for Linagliptin?
Across 329 Part D plans, Linagliptin averages $16.80/unit (NADAC). Lowest available: $16.80/unit. Highest in distribution: $16.80/unit.
Is Linagliptin on the FDA shortage list?
No. Linagliptin is not currently on the FDA Drug Shortage Database.
8 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Same class. Different math.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (8 approvals on file) · NADAC unit costs: CMS NADAC weekly file (3 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.